Brind.

Pete Anevski was appointed CEO of Progyny, and on August 14, 2025, Leerink Partners and Truist made inquiries regarding the company.

3 reports, 1 independent Updated Aug 14

Gone quiet

Reports: 3
Developments: 2
Repetition: 33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Pete Anevski was appointed CEO of Progyny, and on August 14, 2025, Leerink Partners and Truist made inquiries regarding the company.

Who's involved

What this event is mainly about

Progyny, Inc.Leerink partners

How it developed

Newest first. Tap a step to see who reported it.

Aug 14Pete Anevski became CEO of Progyny; Leerink Partners and Truist inquired about the company on Aug 14, 2025.1 source
- StockStory
Aug 12CEO Pete Anevski highlighted the broad appeal of Progyny's solutions.1 source
- StockStory

Keep exploring

The entities involved

Progyny, Inc.
fertility benefits management company

Nothing else this week.
Leerink partners
U.S. investment bank
- Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Mon 08:52
- A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.Sun 22:38

Coverage

Newest first; wire copies grouped

Aug 14StockStory5 Must-Read Analyst Questions From Progyny’s Q2 Earnings Call Progyny’s second quarter results demonstrated stable growth, with management highlighting a return to more typical seasonal patterns in m
Aug 12StockStoryPGNY Q2 Deep Dive: Product Expansion and Client Diversification Drive Upbeat Guidance Fertility benefits company Progyny (NASDAQ:PGNY) reported revenue ahead of Wall Street’s expectations in Q2 CY202
Jun 30Unknown outlet